Nyrada, Inc. · ASX:NYR
Nyrada — Reach Markets Virtual Event: Meet the CEOs (June 2020)
18 slides from Nyrada's conference presentation, Jun 24, 2020
Slide 1: Corporate Presentation for the Reach Markets Virtual Event
For personal use only 24 June 2020 Sydney, Australia Corporate Presentation for the Reach Markets Virtual Event Nyrada Inc. (ASX:NYR) provides to shareholders and the market generally the corporate presentation for the Reach Markets “Meet the CEOs” virtual session at 12 noon today. Nyrada CEO, James
Slide 2: Forward Looking Statements
Forward Looking Statements For personal use only This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “pr
Slide 3: Improving Lives, Offering Hope
For personal use only Improving Lives, Offering Hope Developing New Therapies for Cardiovascular & Neurological Diseases Reach Markets Webcast – Meeting the CEO’s Online Investor Briefing 24 June 2020 James Bonnar - CEO ASX:NYR 1
Slide 4: Important Notice & Disclaimer
Important Notice & Disclaimer For personal use only This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not Although the Company believes that the expectations reflected in the forward looking be considered as an offer or invitation to subscribe for, or purchase any sha
Slide 5: Nyrada Summary
Nyrada Summary For personal use only Recently listed Diverse product portfolio, significant therapeutic and commercial potential, near term milestones. drug discoverer and early stage Cholesterol lowering (PCSK9 inhibitors) program to help up to 70% of patients taking statin drugs, a market worth de
Slide 6: Business Model & Strategy
Business Model & Strategy For personal use only Innovative Treatments Clinical Need Market Potential Strong Patent Protection First-Line / Best in Class Commercialize Early Cardiovascular Neurology Cholesterol-lowering treatment Brain injury treatment (stroke & head trauma) Value inflection point wi
Slide 7: Cholesterol and Cardiovascular Disease
Cholesterol and Cardiovascular Disease For personal use only 1 in 4 Deaths attributed to Cardiovascular Disease • Tobacco use • High blood pressure • High LDL cholesterol Benjamin EJ et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 20
Slide 8: Cholesterol Problem (US)
Cholesterol Problem (US) For personal use only 62.6 million 19.4 million 27.4 million Unable to achieve US adults with elevated Total US adults with LDL-C target despite LDL-C are taking a statin elevated LDL-C taking statin therapy Wong ND et al. Prevalence of the American College of Cardiology/Ame
Slide 9: Current Treatment Options
Current Treatment Options For personal use only Low cost generics available Effective, combined with statin US$16 per 100 pills Suboptimal efficacy Expensive US$5,800 per year Side effects Inconvenient US$19B global cholesterol-lowering drugs market in 2017 (CAGR 4.9%)1 1 Visiongain Market Research
Slide 10: Nyrada Cholesterol-Lowering Solution
Nyrada Cholesterol-Lowering Solution For personal use only Blocks action of PCSK9 on cholesterol receptor Statins increase PCSK9 levels Small molecule PCSK9 inhibitor High PCSK9 = overcomes longstanding challenge high LDL cholesterol of an oral PCSK9 treatment 8
Slide 11: What is Unique?
What is Unique? For personal use only Single pill Convenient Cost- treatment for patient effective 9
Slide 12: Brain Injury Problem
Brain Injury Problem For personal use only Each year in the US: Neurology / physical rehabilitation only existing - High mortality - 2.8 million people sustain therapies - Severe life-long disability a traumatic brain injury (TBI) - One drug class for stroke - High ongoing healthcare (Suitable for l
Slide 13: Nyrada Brain Injury Solution
Nyrada Brain Injury Solution For personal use only Treatment for secondary brain injury following Stroke or TBI - Prevent cell death - Attenuate damaged brain volume - Improve survivability, limit disability, improve quality of life Primary Secondary Disability Injury Injury Level Hours Days Weeks M
Slide 14: Brain Injury Drug Market (US)
Brain Injury Drug Market (US) For personal use only Hospital admissions each year / patients who present <12hr Traumatic Brain Injury 210,000 (Moderate / Severe) 700,000 patients Annual US market size for brain injury combined (approx.) Stroke 490,000 US$20B global severe TBI treatment market in 202
Slide 15: Program Status
Program Status For personal use only First-in-human studies (Phase I) Proof-of-concept Lead optimisation well established advanced - Cholesterol-lowering: late-2021 - Neuroprotection: mid-2022 13
Slide 16: Board of Directors
For personal use only Board of Directors 14
Slide 17: Key Metrics & News Flow
Key Metrics & News Flow For personal use only Market capitalisation H2 H1 H2 H1 $18M 2020 2021 2021 2022 (as at 22 June 2020) Share price Lead product candidate selection for $0.165 cholesterol program: (as at 22 June 2020) Lead product candidate selection for CDIs free float 76,072,869 neuroprotect
Slide 18: Discover More & Follow Us
Discover More & Follow Us For personal use only Neuroprotection Cholesterol-Lowering Recent PCSK9i Animation Animation Publication @nyrada_inc @nyrada_inc www.nyrada.com 16
Nyrada — Reach Markets Virtual Event: Meet the CEOs (June 2020) on 6ix